Literature DB >> 16048929

Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa.

Michelle D Brazas1, Robert E W Hancock.   

Abstract

With few novel antimicrobials in development, resistance to the current selection of antibiotics increasingly encroaches on our ability to control microbial infections. One limitation in our understanding of the basis of the constraints on current therapies is our poor understanding of antibiotic interactions with bacteria on a global scale. Custom DNA microarrays were used to characterize the response of Pseudomonas aeruginosa to ciprofloxacin, a fluoroquinolone commonly used in therapy against chronic infections by this intrinsically resistant bacterium. Of the approximately 5,300 open reading frames (ORFs) on the array, 941 genes showed statistically significant (P </= 0.05) differential expression in response to 0.3x MIC of ciprofloxacin; 554 were promoted and 387 were repressed. Most striking among the responsive genes was the region between PA0613 and PA0648, which codes for the bacteriophage-like R2/F2 pyocins. In this region, virtually every ORF was increased by 0.3x MIC of ciprofloxacin and even more dramatically up-regulated (7- to 19-fold) following treatment with 1x MIC of ciprofloxacin. Pyocin gene expression was confirmed with lux reporter mutants and real-time PCR studies; pyocin-like particles were also present in transmission electron micrographs of supernatants from cells treated with 1x MIC of ciprofloxacin. Interestingly, mutants in this region exhibited >/=8-fold-increased resistance to ciprofloxacin and other fluoroquinolones, demonstrating that this region is a susceptibility determinant. Since this region is known to be variably present in the genomes of clinical isolates of P. aeruginosa (R. K. Ernst et al., Environ. Microbiol. 5:1341-1349, 2003, and M. C. Wolfgang et al., Proc. Natl. Acad. Sci. USA 100:8484-8489, 2003), these findings demonstrate that the R2/F2 pyocin region is a "loaded gun" that can mediate fluoroquinolone susceptibility in P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048929      PMCID: PMC1196232          DOI: 10.1128/AAC.49.8.3222-3227.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment.

Authors:  Robert E. W. Hancock; David P. Speert
Journal:  Drug Resist Updat       Date:  2000-08       Impact factor: 18.500

Review 2.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

3.  Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors.

Authors:  Benjamin Kerr; Margaret A Riley; Marcus W Feldman; Brendan J M Bohannan
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

4.  Prediction of mechanisms of action of antibacterial compounds by gene expression profiling.

Authors:  Bernd Hutter; Christoph Schaab; Sebastian Albrecht; Matthias Borgmann; Nina A Brunner; Christoph Freiberg; Karl Ziegelbauer; Charles O Rock; Igor Ivanov; Hannes Loferer
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors.

Authors:  Wai-Leung Ng; Krystyna M Kazmierczak; Gregory T Robertson; Raymond Gilmour; Malcolm E Winkler
Journal:  J Bacteriol       Date:  2003-01       Impact factor: 3.490

6.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis.

Authors:  H Gmuender; K Kuratli; C P Gray; W Keck; S Evers
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

7.  Regulation of pyocin genes in Pseudomonas aeruginosa by positive (prtN) and negative (prtR) regulatory genes.

Authors:  H Matsui; Y Sano; H Ishihara; T Shinomiya
Journal:  J Bacteriol       Date:  1993-03       Impact factor: 3.490

8.  Aeruginocin tolerant mutants of Pseudomonas aeruginosa.

Authors:  B W Holloway; H Rossiter; D Burgess; J Dodge
Journal:  Genet Res       Date:  1973-12       Impact factor: 1.588

9.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

10.  In vitro and in vivo characterization of pyocin.

Authors:  T B Higerd; C A Baechler; R S Berk
Journal:  J Bacteriol       Date:  1967-06       Impact factor: 3.490

View more
  71 in total

1.  The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.

Authors:  Hsun-Cheng Su; Kevin Ramkissoon; Janet Doolittle; Martha Clark; Jainab Khatun; Ashley Secrest; Matthew C Wolfgang; Morgan C Giddings
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

2.  Bacteriocin-mediated competition in cystic fibrosis lung infections.

Authors:  Melanie Ghoul; Stuart A West; Helle Krogh Johansen; Søren Molin; Odile B Harrison; Martin C J Maiden; Lars Jelsbak; John B Bruce; Ashleigh S Griffin
Journal:  Proc Biol Sci       Date:  2015-09-07       Impact factor: 5.349

3.  Contribution of stress responses to antibiotic tolerance in Pseudomonas aeruginosa biofilms.

Authors:  Philip S Stewart; Michael J Franklin; Kerry S Williamson; James P Folsom; Laura Boegli; Garth A James
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

4.  Antibiotics as intermicrobial signaling agents instead of weapons.

Authors:  J F Linares; I Gustafsson; F Baquero; J L Martinez
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-05       Impact factor: 11.205

5.  Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Eilidh Mowat; Martin J Walshaw; Martin J Ledson; Chloe E James; Craig Winstanley
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

6.  Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility.

Authors:  Elena B M Breidenstein; Bhavjinder K Khaira; Irith Wiegand; Joerg Overhage; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

7.  Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa.

Authors:  Jon Penterman; Pradeep K Singh; Graham C Walker
Journal:  J Bacteriol       Date:  2014-07-14       Impact factor: 3.490

8.  The impact and mechanism of quaternary ammonium compounds on the transmission of antibiotic resistance genes.

Authors:  Yue Han; Zhen-Chao Zhou; Lin Zhu; Yuan-Yuan Wei; Wan-Qiu Feng; Lan Xu; Yang Liu; Ze-Jun Lin; Xin-Yi Shuai; Zhi-Jian Zhang; Hong Chen
Journal:  Environ Sci Pollut Res Int       Date:  2019-08-01       Impact factor: 4.223

9.  In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms.

Authors:  Do-Yeon Cho; Dong-Jin Lim; Calvin Mackey; Christopher G Weeks; Jaime A Peña Garcia; Daniel Skinner; Shaoyan Zhang; Justin McCormick; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2019-01-31       Impact factor: 3.858

10.  Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.

Authors:  Christian van Delden; Malcolm G P Page; Thilo Köhler
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.